Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Pharvaris Netherlands B.V.
Sponsor

Pharvaris Netherlands B.V.

The Netherlands J.h. Oortweg 21, 2333 CH Leiden, The Netherlands

About the sponsor

Pharvaris Netherlands B.V. focuses on preventive treatment strategies for hereditary angioedema, with research centred on reducing the frequency of swelling attacks in adults and adolescents living with C1 inhibitor deficiency.

  • Long-term prophylactic therapy
  • Attack prevention in HAE
  • Oral treatment for recurrent angioedema

Its clinical portfolio includes work in both HAE due to C1-inhibitor deficiency and broader hereditary angioedema populations.

About Specializations

Pharvaris Netherlands B.V. runs clinical trials in conditions such as Hereditary angioedema, Hereditary angioedema with C1 esterase inhibitor deficiency, Acquired C1 inhibitor deficiency, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Acquired C1 inhibitor deficiency

Recruiting

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Hereditary angioedema

Recruiting

Study of deucrictibant tablets for prevention of hereditary angioedema attacks in adults and adolescents

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Hereditary angioedema with C1 esterase inhibitor deficiency

Recruiting

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Hereditary angioedema

Not recruiting

Study of Deucrictibant Extended-Release Tablets for Prevention of Hereditary Angioedema Attacks in Adults and Adolescents

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

Study on Oral PHA-022121 for Preventing Angioedema Attacks in Patients with Hereditary Angioedema

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(S)-N-(1-Deutero-1-(3-Chloro-5-Fluoro-2-((2-Methyl-4-(1-Methyl-1H-1,2,4-Triazol-5-Yl)Quinolin-8-Yloxy)Methyl)Phenyl)Ethyl)-2-(Difluoromethoxy)Acetamide
  • Sponsor:Pharvaris Netherlands B.V.

Hereditary angioedema with C1 esterase inhibitor deficiency

Not recruiting

Study on Deucrictibant and Icatibant for Treating Hereditary Angioedema Attacks in Adolescents and Adults

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.